Novo Nordisk A/S (CPH:NOVO.B)
263.00
-2.15 (-0.81%)
Nov 20, 2026, 11:49 AM CET
Novo Nordisk Employees
Novo Nordisk had 66,700 employees as of June 30, 2026. The number of employees decreased by 11,687 or 14.91% compared to the same quarter last year. That makes Novo Nordisk the 535th largest employer in the world and 4th in Denmark.
Employees
66,700
Change (1Y)
-11,687
Growth (1Y)
-14.91%
Revenue / Employee
4.83M DKK
Profits / Employee
1.64M DKK
Market Cap
1.16T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 66,700 | -11,687 | -14.91% | 66,700 | 0 |
| Mar 31, 2026 | 67,900 | -9,506 | -12.28% | 67,900 | 0 |
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% | 68,794 | 711 |
| Sep 30, 2025 | 78,554 | 6,674 | 9.28% | 78,554 | 0 |
| Jun 30, 2025 | 78,387 | 9,127 | 13.18% | 78,387 | 0 |
| Mar 31, 2025 | 77,406 | 11,391 | 17.26% | 77,406 | 0 |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% | 76,302 | 1,047 |
| Sep 30, 2024 | 71,880 | 10,468 | 17.05% | 71,880 | 0 |
| Jun 30, 2024 | 69,260 | 9,923 | 16.72% | 69,260 | 0 |
| Mar 31, 2024 | 66,015 | 8,926 | 15.64% | 66,015 | 0 |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% | 63,370 | 949 |
| Sep 30, 2023 | 61,412 | 8,716 | 16.54% | 61,412 | 0 |
| Jun 30, 2023 | 59,337 | 8,521 | 16.77% | 59,337 | 0 |
| Mar 31, 2023 | 57,089 | 7,794 | 15.81% | 57,089 | 0 |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% | 54,393 | 792 |
| Sep 30, 2022 | 52,696 | 5,714 | 12.16% | 52,696 | 0 |
| Jun 30, 2022 | 50,816 | 4,845 | 10.54% | 50,816 | 0 |
| Mar 31, 2022 | 49,295 | 4,138 | 9.16% | 49,295 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Demant | 26,616 |
| Coloplast | 17,270 |
| GN Store Nord | 7,856 |
| H. Lundbeck | 5,000 |
| Ambu A/S | 4,664 |
| Embla Medical | 4,500 |
| Genmab | 3,244 |
| ALK-Abelló | 2,773 |
Novo Nordisk News
- 20 hours ago - Lexaria reports final dosing in Human Pilot Study #7 of DHT-sema - TheFly
- 1 day ago - Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says - Reuters
- 1 day ago - Novo Nordisk put volume heavy and directionally bearish - TheFly
- 2 days ago - Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027? - The Motley Fool
- 2 days ago - Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue - The Motley Fool
- 3 days ago - Novo Nordisk presents new research that includes cagrilintide study - TheFly
- 3 days ago - Novo's Wegovy cuts BMI by 17.4% in obese children aged 6 to 11 in late-stage trial - Stock Analysis
- 3 days ago - Novo says Wegovy injection lowers BMI and obesity rates in children in trial - CNBC